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Abstract. Envenomation by poisonous animals is a neglected condition according to the World Health Organization
(WHO). Antivenoms are included in the WHO Essential Medicines List. It has been assumed that immunoglobulin G
(IgG) antivenoms could activate the complement system through Fc and induce early adverse reactions (EARs).
However, data in the literature indicate that F(ab’)2 fragments can also activate the complement system. Herein, we
show that several batches of IgG and F(ab’)2 antivenoms from the Butantan, Vital Brazil, and Clodomiro Picado
Institutes activated the complement classical pathway and induced the production of C3a; however, only those
antivenoms from Clodomiro Picado generated C5a. Different protein profiles (IgG heavy chain, protein contaminants,
and aggregates) were observed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and Western
blot analyses. Our results show that various antivenoms from different producers are able to activate the classical
pathway of the complement system and generate anaphylatoxins, and these findings suggest that factors, such as
composition, contaminant proteins, and aggregates, may influence the anticomplementary activity of antivenoms
in vitro. Therefore, there is a need to further improve antivenom production methods to reduce their anticomplementary
activity and potential to cause EARs.
INTRODUCTION
Envenomation is a relevant public health issue1 that has been
included, since 2009, in the list of neglected tropical diseases
and conditions of the World Health Organization (WHO).2
The only available treatment of animal envenomation is the
parenteral administration of specific antivenom; therefore,
animal-derived antivenoms are included on the WHO Essen-
tial Medicines List.3 Antivenoms are obtained from the
plasma of immunized animals, usually horses or sheep, and
may consist of whole immunoglobulin G (IgG) molecules
(150 kDa) or F(ab’)2 (100 kDa) or F(ab) (50 kDa) fragments;
the latter two are devoid of Fc portion and obtained by
pepsin and papain digestion, respectively.4,5 Several fraction-
ation methods have been used to purify IgG or its fragments,
including salting out with ammonium sulphate, which precipi-
tates Igs, and fractionation with caprylic acid, which precipi-
tates non-IgG proteins from plasma.4,6
The option to produce F(ab’)2 or Fab antivenoms is largely
based on the hypothesis that early adverse reactions (EARs),
observed in a number of patients submitted to the antivenom
therapy, could be caused by the generation of anaphylatoxins
because of complement activation through the Fc portion of
IgG. These reactions range from mild and moderate (charac-
terized by tachycardia, shivering, chills, fever, vomit, and urti-
caria) to severe anaphylaxis (with bronchospasm, dyspnea,
hypotension, and hypoxia) and can result in death.7,8
However, various studies have shown that both types of
antivenoms can activate the complement system in vitro9,10
and induce EARs in patients.11,12 Some data highlight the
impact of the fractionation protocol on the induction of EARs.
It was shown that IgG antivenom precipitated by ammonium
sulphate had more aggregates and induced a higher incidence
of EARs than IgG antivenom precipitated by caprylic acid.13
Furthermore, depending on the concentration of caprylic acid
used in the fractionation step, high-molecular mass protein
aggregates also can be formed in IgG preparations.6
It was shown that horse and sheep IgG antivenoms induced
higher complement activation and were more immunogenic
than camel IgG antivenom.14 There is also a general consensus
that adverse effects are directly related to the amount of
infused heterologous proteins,15 although it was shown that
homologous proteins (human IgG) also activate the comple-
ment system.16 The addition of thimerosal and/or phenol to
IgG antivenoms increased the formation of dimeric and poly-
meric IgGs and induced higher complement activation com-
pared with antivenoms formulated without preservatives.17 All
of these data indicate the lack of consensus in the literature
regarding which types of antivenom induce fewer EARs and in
particular, which mechanisms are involved in the genesis of
these reactions, including the role of the complement system.
The complement system can initially be activated by three
pathways (alternative, classical, and lectin),18 and during its
activation, cleavage of the C3, C4, and C5 components results
in the generation of anaphylatoxins (C3a, C4a, and C5a).
Anaphylatoxins play an important role in the inflammatory
response, inducing (1) mast cell degranulation, which releases
vasoactive mediators such as histamine; (2) neutrophil and
monocyte chemoattraction to inflammatory sites; (3) oxidative
burst stimulation; and (4) proinflammatory cytokine release.18
The massive generation of anaphylatoxins can induce non-
IgE–dependent anaphylaxis.
Herein, we aimed to evaluate the anticomplementary activity
of horse IgG and F(ab’)2 antivenoms produced by Butantan,
Vital Brazil, and Clodomiro Picado Institutes and correlate the
complement activation with some important characteristics of
the antivenoms, such as protein content, presence of Fc por-
tion, and amount of protein aggregates.
MATERIALS ANDMETHODS
Reagents and buffers. Mannan, bovine serum albumin
(BSA), orthophenylenediamine (OPD), ethylene diamine
tetracetic acid (EDTA), ethylene glycol bis-(b-aminoethyl
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ether)-N,N,N,N’-tetracetic acid (EGTA), and rabbit anti-
horse IgG labeled with alkaline phosphatase were purchased
from Sigma (St. Louis, MO). Tween 20 was from Labsynth
(Diadema, SP, Brazil). Goat IgG anti-human C4 was from
Quidel Corporation (San Diego, CA). Rabbit anti-goat IgGs
labeled with horseradish peroxidase, nitroblue tetrazolium
(NBT), and 5-bromo-4-chloro- 3-indolyl-phosphate (BCIP)
were from Promega Corporation (Madison, WI). The follow-
ing buffers were used: alsever old solution (114 mM sodium
citrate, 27 mM D-glucose, 72 mM sodium chloride, pH 6.1);
phosphate buffered saline (PBS; 8.1 mM disodium phosphate,
1.5 mM potassium phosphate, 137 mM sodium chloride,
2.7 mM potassium chloride, pH 7.4); veronal buffered saline
(VBS++; 2.8 mM barbituric acid, 145.5 mM sodium chloride,
Table 1
Samples of antivenoms from Butantan, Vital Brazil, and Clodomiro Picado Institutes
Antivenom/institute/batch Fabrication Additional information
Anti-Bot
Butantan
0707138/D 06/2007 1 mL neutralizes 5 mg Bothrops jararaca venom
0805063/D 04/2008
0901004/B 01/2009
Vital Brazil
095103 G 11/2009
Anti-Bot–Crot
Butantan
0706120 05/2007 1 mL neutralizes 5 mg B. jararaca venom and 1.5 mg Crotalus durissus terrificus venom
0905084/A 04/2009
Vital Brazil
095402 A 12/2009
Anti-Bot–Lac
Butantan
0705098/A 04/2007 1 mL neutralizes 5 mg B. jararaca venom and 3 mg Lachesis muta venom
0806068/B 05/2008
0906133 06/2009
Vital Brazil
095903 A 01/2010
Anti-Crot
Butantan
0710211/B 09/2007 1 mL neutralizes 1.5 mg C. durissus terrificus venom
0810144/B 09/2008
0908162/B 07/2009
Vital Brazil
095208 A 11/2009
Anti-Elap BR
Butantan
0706111/B 05/2007 1 mL neutralizes 1.5 mgMicrurus frontalis venom
0810141 09/2008
1002031/A 12/2009
Anti-Arac
Butantan
0706121 05/2007 1 mL neutralizes 1.5 MLD Tityus serrulatus venom, 1.5 MLD Phoneutria nigriventer venom,
and 15 MND Loxosceles gaucho venom0806074/A 05/2008
0905100/A 04/2009
Anti-Scorp
Butantan
0707135/C 06/2007 1 mL neutralizes 1.5 MLD T. serrulatus venom
0804038/A 02/2008
0905104/A 04/2009
Anti-Lon
Butantan
0801006 12/2007 1 mL neutralizes 0.35 mg Lonomia obliqua venom
0806071 05/2008
0906113 04/2009
Anti-Elap CR
Clodomiro Picado
4300708ACLQ 07/2008 1 mL neutralizes 0.3 mgMicrurus nigrocinctus venom, 0.3 mgM. d. carinicaudus venom,
and 0.125 mgM. fulvius venom4480909ACLQ 09/2009
Anti-Bot–Crot–Lac
Clodomiro Picado
4450609POLQ 06/2009 1 mL neutralizes 3 mg B. asper venom, 2 mg C. durissus venom, and 3 mg L. muta venom
4590410POLQ 04/2010
Echi-Tab-Plus
Clodomiro Picado
4600510PALQ 05/2010 1 mL neutralizes 3 mg Echis ocellatus venom, 2 mg Bitis arietans venom,
and 0.2 mg Naja nigricollis venom
Arac = Arachnidic; Bot = Bothropic; Crot = Crotalic; Elap BR = Elapidic Brazil; Elap CR = Elapidic Costa Rica; Lac = Lachetic; Lon = Lonomic; MLD = minimal lethal dose; MND = minimal
necrotizing dose; Scorp = Scorpionic.
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0.8 mMmagnesium chloride, 0.3 mM calcium chloride, 0.9 mM
Na-barbital, pH 7.2); VBS containing 0.1% BSA (BVB++); and
alternative pathway buffer (APB; 150 mM sodium chloride,
7 mM magnesium chloride, 5 mM Na-barbital, 10 mM EGTA,
pH 7.4).
Horse IgG and F(ab’)2 antivenoms. Commercial horse
antivenoms, produced against the venoms from different
animal genera were obtained from the Butantan (Sa˜o Paulo,
Brazil), Vital Brazil (Nitero´i, Brazil), and Clodomiro Picado
(San Jose´, Costa Rica) Institutes, totaling 32 batches (64 vials)
produced between 2007 and 2010 (Table 1). Antivenoms from
the Butantan and Vital Brazil Institutes consisted of F(ab’)2
fragments obtained by pepsin digestion and ammonium sulphate
precipitation,19 whereas antivenoms from the Clodomiro Picado
Institute contained whole IgG purified by caprylic acid precipi-
tation.20 Antivenoms passed routine quality control tests in
manufacturing laboratories and were used within their shelf life.
Ethics statement. Human blood was obtained from adult
healthy donors who knew the objectives of the study and signed
the corresponding informed consent form approved by the
National Commission on Research Ethics (CAAE02001612
.6.0000.0071). All experimental procedures involving animals
were in accordance with the ethical principles in animal research
adopted by the Brazilian Society of Animal Science and the
National Brazilian Legislation (number 11.794/08). Protocols
were approved by the Institutional Animal Care and Use Com-
mittee (protocol approval number 904/12).
Table 2
Volume of each antivenom incubated with normal human serum
in vitro based on the maximum volume administered to patients
proportional to the volume of circulating plasma
Antivenom
Maximum volume
administered to patients
(volume [mL]/2.75 L plasma)
Incubation volume
(volume [mL]/200 mL NHS)
Anti-Bot 120 8.73
Anti-Bot-Crot 200 14.55
Anti-Bot-Lac 200 14.55
Anti-Crot 200 14.55
Anti-Elap BR 100 7.27
Anti-Arac 50 3.64
Anti-Scorp 30 2.18
Anti-Lon 100 7.27
Anti-Elap CR 100 7.27
Anti-Bot-Crot-Lac 150 10.91
Echi-Tab-Plus 40 2.91
Figure 1. Classical complement consumption by the antivenoms. NHS was incubated with antivenoms from the (A) Butantan, (B) Vital
Brazil, and (C) Clodomiro Picado Institutes or saline as a negative control. The activation of the complement classical pathway was measured by
the residual lytic activity of NHS on sheep erythrocytes, and the results were expressed as the percentage of CH50/mL in relation to NHS
incubated with saline (100%). Data represent mean ± SD of two independent experiments. *P < 0.05; **P < 0.01; ***P < 0.0001 compared with
saline. Arac = Arachnidic; Bot = Bothropic; Crot = Crotalic; Elap = Elapidic; Lac = Lachetic; Lon = Lonomic; Scorp = Scorpionic.
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Normal human serum. Blood samples from adult healthy
donors were collected without anticoagulant and allowed to
clot for 4 hours at 4°C. After centrifugation, normal human
serum (NHS) was collected and stored at −80°C.
Sheep and rabbit erythrocytes. Sheep and rabbit erythro-
cytes were used as target cells in classical and alternative path-
way hemolytic assays, respectively. Blood was collected in
Alsever anticoagulant and stored at 4°C. Sheep blood samples
were provided by the Sa˜o Joaquim Farm (Butantan Institute).
Incubation of antivenoms with NHS. Antivenoms were
incubated with NHS as a source of complement for 1 hour at
37°C. The volume of NHS was the same for all incubations
(200 mL), but the sample volume varied between the different
antivenoms (Table 2) based on an estimation of the maximum
volume of each antivenom administered to patients in severe
accidents in proportion to the average volume of circulating
plasma in a normal human adult. For practical purposes,
a normal human adult was considered to have 2.75 L circulat-
ing plasma (55% of 5 L blood). For each control group, NHS
was incubated with a corresponding volume of sterile non-
pyrogenic saline (0.9% sodium chloride).
Complement activation by the classical, alternative, and
lectin pathways. Activation of the classical and alternative
complement pathways by the antivenoms was measured in
hemolytic assays by determining the residual hemolytic activ-
ity of NHS on sheep and rabbit erythrocytes, respectively.
Experiments were performed as previously described.21 The
results were expressed as the percentage of CH50/mL (clas-
sical pathway) or AP50/mL (alternative pathway) activation
compared with NHS incubated with saline (100%). Activa-
tion of the lectin complement pathway by the antivenoms
was determined by enzyme-linked immunosorbent assay
(ELISA), which detected the deposition of C4b in mannan-
sensitized plates as previously described.21
Detection of anaphylatoxins. After incubating NHS with
antivenoms or saline (control) as described above, the reac-
tions were stopped by the addition of 10 mM EDTA, and the
concentrations of C3a/C3a desArg and C5a/C5a desArg were
determined by ELISA (OptEIA ELISA Kit; BD Biosciences,
San Jose, CA) following the manufacturer’s instructions.
Protein concentration. To verify whether the complement
activation by the antivenoms could be related to the amount
of antivenom protein incubated with NHS, the protein
concentrations of the antivenoms were determined using
the BCA method (Pierce BCA Protein Assay Kit; Pierce,
Rockford, IL) according to the manufacturer’s instructions
with BSA as standard.
Polyacrylamide gel electrophoresis and Western blots.
To determine protein composition profiles, the most recent
samples of each antivenom were subjected to sodium dodecyl
Figure 2. Generation of C3a/C3a desArg by antivenoms. NHS was incubated with antivenoms from the (A) Butantan, (B) Vital Brazil,
and (C) Clodomiro Picado Institutes or saline as a negative control. The generation of C3a/C3a desArg was detected by ELISA. Data represent
mean ± SD of two independent experiments. *P < 0.05; **P < 0.01; ***P < 0.0001 compared with saline.
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sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and
Western blot analysis under non-reducing and reducing con-
ditions. Briefly, samples were diluted in saline solution (0.9%
sodium chloride) to achieve the protein concentration of
2 mg/mL; 10 mL each diluted sample (20 mg protein) were
then mixed with the same volume of reducing or non-reducing
buffer and subjected to 12% SDS-PAGE.22 Molecular mass
standards (Invitrogen/Life Technologies, Carlsbad, CA) were
Figure 3. Generation of C5a/C5a desArg by antivenoms. NHS was incubated with antivenoms from the (A) Butantan, (B) Vital Brazil,
and (C) Clodomiro Picado Institutes or saline as a negative control. The generation of C5a/C5a desArg was detected by ELISA. Data represent
mean ± SD of two independent experiments. **P < 0.01; ***P < 0.0001 compared with saline.
Figure 4. Amount of antivenom protein in the experimental condition. The protein concentrations of all antivenom samples were determined
by the BCA method. Based on the protein concentration of each antivenom and the specific volume used in the incubation with NHS, the amount
of antivenom protein in each incubation was calculated. The results are expressed as the amount of antivenom protein (micrograms) per 200 mL
NHS and represent the mean of two independent experiments.
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included in all runs, which were performed at 100 V. Gels
were stained with silver.23 For Western blot assays,24 proteins
on unstained gels were transferred to nitrocellulose mem-
branes at 150 mA. After transfer, reactions were performed
to detect horse IgG as previously described.25
Statistical analysis.Data were analyzed by one-way analysis
of variance (ANOVA) followed by Tukey’s post-test, and
differences with P values that were less than 0.05 were con-
sidered to be statistically significant. For correlation analysis,
Pearson’s correlation coefficient, for which values close to 1.0
or −1.0 indicate positive or negative correlations, respectively,
was calculated.
RESULTS
Complement consumption by the antivenoms. The classical
pathway was activated by several antivenoms from the three
institutes, which was shown by the reduction of the CH50/mL
compared with the control (Figure 1). This reduction was
statistically significant for all batches of anti-Elapidic and
anti-Lonomic antivenoms from the Butantan Institute as well
as for one batch of anti-Crotalic antivenom (2009) and one
batch of anti-Arachnidic antivenom (2007) (Figure 1A). Anti-
Bothropic–Crotalic and anti-Crotalic antivenoms from the
Vital Brazil Institute also significantly interfered with the clas-
sical pathway (Figure 1B) as well as the two batches of anti-
Bothropic–Crotalic–Lachetic antivenom from the Clodomiro
Picado Institute (Figure 1C). None of the antivenoms tested
in this study activated the lectin or alternative pathways (data
not shown).
Generation of anaphylatoxins by the antivenoms. To better
investigate the complement activation by the antivenoms, the
generation of anaphylatoxins was determined. Most anti-
venoms from the three institutes induced the generation of
C3a/C3a desArg when incubated with NHS (Figure 2), which
was also observed in samples where the consumption of clas-
sical pathway components was not detected (Figure 1). Inter-
estingly, antivenoms from the Butantan and Vital Brazil
Institutes did not induce the generation of C5a/C5a desArg
(Figure 3A and B), whereas all the antivenoms from the
Clodomiro Picado Institute induced this potent anaphylatoxin
(Figure 3C).
Protein concentration of the antivenoms. To verify whether
the complement activation by the antivenoms could be related
to the amount of antivenom protein incubated with NHS,
Figure 5. SDS-PAGE analyses of antivenoms in non-reduction conditions. The most recent antivenom samples from the (A) Butantan,
(B) Vital Brazil, and (C) Clodomiro Picado Institutes were subjected to 12% PAGE under non-reducing condition. Proteins on gels were stained
with silver. Molecular mass standards are shown on the left.
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the protein concentration of all the samples was determined
(data not shown). Based on the protein concentration of the
samples and the volume of each antivenom incubated with
NHS (Table 2), the amount of antivenom protein in each
incubation was calculated (Figure 4). There was no statis-
tical correlation between the amount of antivenom pro-
tein and the consumption of classical pathway components
(Pearson r = 0.16, P > 0.05) or the generation of C3a/C3a
desArg (Pearson r = − 0.15, P > 0.05) or C5a/C5a desArg
(Pearson r = − 0.30, P > 0.05).
SDS-PAGE and Western blot analysis of the antivenoms.
To determine the protein composition profiles and their pos-
sible correlation with complement activation, the most recent
samples of each antivenom were submitted to SDS-PAGE
and Western blot analyses under non-reducing and reducing
conditions. Under non-reducing condition, various bands, with
molecular masses between 30 and 160 kDa, were observed in
all the antivenoms analyzed, and some antivenoms also showed
a high-molecular mass band with approximately 220 kDa
(Figure 5), indicating the presence of high-molecular mass
aggregates.13 Most of the non-reduced bands were recognized
by the anti-horse IgG antibody in the Western blot reactions
(Figure 6), suggesting the presence of IgG or its fragments
on aggregates of different molecular masses. These aggregates
included high-molecular mass aggregates, with more than
180 kDa (Figure 6).
The electrophoretic analysis, under reducing condition,
revealed the presence of two major bands with molecular
masses between 25 and 30 kDa in all samples from the
Butantan and Vital Brazil Institutes as well as several other
proteins with molecular masses lower than 20 kDa (Figure 7A
and B). One minor band of approximately 50 kDa was also
observed in some antivenoms from the Butantan Institute
(Figure 7A). Antivenoms from the Clodomiro Picado Insti-
tute exhibited a major band of approximately 25–30 kDa,
three bands from 40 to 60 kDa, and also, several other minor
components with different molecular masses (Figure 7C).
Western blot analysis under reducing condition revealed the
existence of IgG heavy (50 kDa) and light (25 kDa) chains26 in
several antivenoms from the Butantan Institute (Figure 8A),
indicating that the cleavage of the antibodies for the produc-
tion of F(ab’)2 fragments was not complete. In the antivenoms
from the Vital Brazil Institute, only one band of approximately
25 kDa was detected (Figure 8B), which most likely includes
IgG light chain and pepsin-digested IgG heavy chain frag-
ments. As expected, IgG heavy and light chains were detected
in all the samples from the Clodomiro Picado Institute
(Figure 8C), because they contain whole IgGs. However, several
other bands were also detected in these samples, including one
of approximately 115 kDa (Figure 8C), suggesting that the
aggregates present in these antivenoms were not completely
disrupted in our experiments.
Figure 6. Western blot analyses of antivenoms in non-reduction conditions. The most recent antivenom samples from the (A) Butantan,
(B) Vital Brazil, and (C) Clodomiro Picado Institutes were subjected to 12% PAGE under non-reducing condition. Proteins on gels were
transferred to nitrocellulose membranes for the detection of horse IgG. Molecular mass standards are shown on the left.
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DISCUSSION
In the present work, the anticomplementary activity of com-
mercial horse antivenoms produced by the Butantan, Vital
Brazil, and Clodomiro Picado Institutes between 2007 and 2010
was evaluated in in vitro assays. Antivenoms from the Butantan
and Vital Brazil Institutes consist of F(ab’)2 fragments obtained
by pepsin digestion and ammonium sulphate precipitation,19
whereas antivenoms from the Clodomiro Picado Institute con-
tain whole IgGs purified by caprylic acid fractionation.20
Analysis of complement activation was performed after
incubating the antivenoms with NHS. The proportion of anti-
venom to NHS was based on the estimation of the maximum
volume of each antivenom administered to patients in severe
accidents in proportion to the average volume of circulating
plasma in normal adult humans. This protocol results in differ-
ent amounts of antivenom protein added to each incubation
mixture. Although this limitation concerns the comparison
between different samples on the basis of the amount of pro-
tein, our experimental rationale was adopted as an effort to
partially reproduce, in vitro the conditions to which patients
are subjected during antivenom therapy.
Under these experimental conditions, none of the anti-
venoms tested activated the lectin or alternative pathways,
but some of them interfered with the classical pathway. Inter-
estingly, classical pathway consumption was also induced by
antivenoms devoid of Fc portion (i.e., antivenoms in which
the IgG heavy chain was not detected in the Western blot
reactions). It has been shown that the hinge portion of IgG,
which is preserved in F(ab’)2 fragments, has an important role
in C1q binding.27 Additionally, F(ab’)2-containing immune
complexes, together with naturally occurring antihinge anti-
bodies, can induce complement activation.28 These findings
corroborate that removal of Fc from equine IgGs by pepsin
digestion does not eliminate complement activation in vitro.
The potential clinical relevance of complement activation
by antivenoms is related to the possible generation of ana-
phylatoxins. C5a is the most potent anaphylatoxin, and it is
followed by C3a and C4a.29 These anaphylatoxins contain a
C-terminal arginine residue that is rapidly cleaved by serum
carboxypeptidases, resulting in desArg derivatives. This
mechanism is involved in the regulation of the complement
system,18,29 and the detection of desArg derivatives also
reflects the generation of anaphylatoxins. In this study, the
generation of C3a and C5a by the antivenoms was analyzed
by detecting C3a/C3a desArg and C5a/C5a desArg.
Several antivenoms from the three institutes induced the
production of C3a, which was also observed in samples where
Figure 7. SDS-PAGE analyses of antivenoms in reduction conditions. The most recent antivenom samples from the (A) Butantan, (B) Vital
Brazil, and (C) Clodomiro Picado Institutes were subjected to 12% PAGE under reducing condition. Proteins on gels were stained with silver.
Molecular mass standards are shown on the left.
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the consumption of classical pathway components was not
detected. This production probably occurred because of differ-
ent analytical sensitivity of the two methodologies used (i.e.,
hemolytic assay and ELISA). The release of C3a was not
related to the presence of Fc, once antivenoms from Vital
Brazil Institute, none of which contained the Fc fraction, also
induced the production of this anaphylatoxin. The genera-
tion of C5a was only induced by the antivenoms from the
Clodomiro Picado Institute. This finding can be related to the
presence of higher amounts of IgG heavy chain and protein
aggregates in Clodomiro Picado Institute antivenoms, an issue
that deserves additional investigation.
The generation of anaphylatoxins by antivenoms might be
related to the induction of EARs in patients, because it could
be involved with the non-IgE–dependent anaphylatic reac-
tions. Thus, it could be reasonable to suggest that the severity
of these reactions might be related to the amount and type of
anaphylatoxins (C3a or C5a) generated in vivo. In this case,
the concomitant release of C5a and C3a might induce more
severe reactions than the release of C3a alone. Based on this
hypothesis and our observations, it could be suggested that
Clodomiro Picado antivenoms might cause a higher incidence
of severe EARs than Butantan and Vital Brazil antivenoms.
However, clinical trials using IgG antivenoms produced at the
Clodomiro Picado Institute found that severe EARs were
infrequent.13,30 A study comparing the concentrations of
anaphylatoxins and other inflammatory mediators in plasma
from Sri Lanka snakebite victims before and after antivenom
therapy was recently published.31 Sri Lankan snake envenoming
induced complement activation and release of inflammatory
mediators, and antivenom therapy further increased the levels
of these mediators but not anaphylatoxins. The differences
between our results and the results from the in vivo studies
can be because of differences in the sensitivities of the methods
used for the determination of complement activation and gen-
eration of anaphylatoxins and/or types of antivenoms. More-
over, it cannot be ruled out that the in vitro results do not
translate into in vivo effects.
To verify the correlation between complement activation
and the amount of antivenom protein added in the incuba-
tions, the protein concentrations of the samples were deter-
mined (data not shown). Based on the protein concentrations
of the samples and the volume of each antivenom incubated
with NHS, the amount of antivenom protein in each incuba-
tion was calculated. The amount of antivenom protein did
not significantly correlate with the percentage of CH50/mL
or the generation of C3a and C5a, suggesting that it is not the
main factor involved in the complement activation by the
antivenoms in vitro.
SDS-PAGE and Western blot analyses of the antivenoms
under non-reducing condition showed the presence of high-
molecular mass aggregates containing IgG molecules in several
samples, mainly those samples from the Clodomiro Picado
Institute; however, previous studies showed that the amount
of protein aggregate in antivenoms from this manufacturer
is ~3%.13,32 IgG aggregates can be formed by F(ab)–F(ab) or
Fc–Fc interactions and occur after prolonged storage times,
increasing the immunogenicity and modifying the physical
properties of antivenoms.33 Low-molecular mass proteins were
also detected in reduced samples, but they did not correspond
Figure 8. Western blot analyses of antivenoms in reduction conditions. The most recent antivenom samples from the (A) Butantan, (B) Vital
Brazil, and (C) Clodomiro Picado Institutes were subjected to 12% PAGE under reducing condition. Proteins on gels were transferred
to nitrocellulose membranes for the detection of horse IgG. Molecular mass standards are shown on the left. H = IgG heavy chain; L = IgG light
chain; pdH = pepsin-digested IgG heavy chain.
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to Ig degradation products, which was shown by the Western
blot reactions; thus, they were considered protein contaminants.
In conclusion, our results show that different types of
antivenoms can activate the classical pathway of the com-
plement system and generate anaphylatoxins, events that
may be associated with various antivenom characteristics,
such as composition, contaminant proteins, and aggregates.
The role of the generation of C5a by the antivenoms in the
EARS still needs additional investigation; however, the
detection of C5a may be a useful mark for the presence of
protein aggregates, which can help the quality control pro-
cess for antivenom production.
Received October 12, 2013. Accepted for publication December 16,
2013.
Published online January 20, 2014.
Acknowledgments: We thank Guillermo Leo´n for critical reading
of the manuscript.
Financial support: This work was supported by Sa˜o Paulo Research
Foundation (FAPESP) Grant 2011/51869-1.
Authors’ addresses: Carla Cristina Squaiella-Baptista˜o and Denise
V. Tambourgi, Laborato´rio de Imunoquı´mica, Instituto Butantan,
Sa˜o Paulo, SP, Brazil, E-mails: carla.baptistao@butantan.gov.br and
denise.tambourgi@butantan.gov.br. Jose´ Roberto Marcelino, Sec¸a˜o
de Processamento de Plasmas Hiperimunes, Instituto Butantan,
Sa˜o Paulo, SP, Brazil, E-mail: jose.marcelino@butantan.gov.br. Luiz
Eduardo Ribeiro da Cunha, Instituto Vital Brazil, Nitero´i, RJ, Brazil,
E-mail: luis.eduardo@vitalbrazil.rj.gov.br. Jose´ Marı´a Gutie´rrez,
Instituto Clodomiro Picado, Facultad de Microbiologı´a, Universidad
de Costa Rica, San Jose´, Costa Rica, E-mail: jose.gutierrez@ucr.ac.cr.
REFERENCES
1. World Health Organization, 2007. Rabies and Envenomings: A
Neglected Public Health Issue: Report of a Consultative Meeting.
Available at: http://www.who.int/bloodproducts/animal_sera/
Rabies.pdf. Accessed February 5, 2013.
2. World Health Organization, 2009. The 17 Neglected Tropical
Diseases. Available at: http://www.who.int/neglected_diseases/
diseases/en. Accessed February 5, 2013.
3. World Health Organization, 2011. WHO Model List of Essential
Medicines. Available at: http://whqlibdoc.who.int/hq/2011/
a95053_eng.pdf. Accessed February 5, 2013.
4. World Health Organization, 2010. Guidelines for the Produc-
tion, Control and Regulation of Snake Antivenom Immuno-
globulins. Available at: http://www.who.int/bloodproducts/
snake_antivenoms/snakeantivenomguideline.pdf. Accessed
February 5, 2013.
5. Lavonas EJ, 2012. Antivenoms for snakebite: design, function
and controversies. Curr Pharm Biotechnol 13: 1980–1986.
6. Eursakun S, Simsiriwong P, Ratanabanangkoon K, 2012. Studies
on the fractionation of equine antivenom IgG by combinations
of ammonium sulfate and caprylic acid. Toxicon 60: 1022–1029.
7. Cardoso JL, Fan HW, Franc¸a FO, Jorge MT, Leite RP, Nishioka
SA, Avila A, Sano-Martins IS, Tomy SC, Santoro ML,
Chudzinski AM, Castro SCB, Kamiguti AS, Kelen EMA,
Hirata MH, Mirandola RMS, Theakston RDG, Warrell
DA, 1993. Randomized comparative trial of three anti-
venoms in the treatment of envenoming by lance-headed
vipers (Bothrops jararaca) in Sa˜o Paulo, Brazil. Q J Med 86:
315–325.
8. Isbister GK, Shahmy S,Mohamed F, Abeysinghe C, Karunathilake
H, Ariaratnam A, 2012. A randomised controlled trial of
two infusion rates to decrease reactions to antivenom. PLoS
One 7: e38739.
9. Morais JF, de Freitas MC, Yamaguchi IK, dos Santos MC,
da Silva WD, 1994. Snake antivenoms from hyperimmunized
horses: comparison of the antivenom activity and biological
properties of their whole IgG and F(ab’)2 fragments. Toxicon
32: 725–734.
10. Leo´n G, Monge M, Rojas E, Lomonte B, Gutie´rrez JM, 2001.
Comparison between IgG and F(ab’)2 polyvalent antivenoms:
neutralization of systemic effects induced by Bothrops asper
venom in mice, extravasation to muscle tissue, and potential
for induction of adverse reactions. Toxicon 39: 793–801.
11. Otero-Patin˜o R, Cardoso JLC, Higashi HG, Nu´n˜ez V, Dı´az A,
Toro MF, Garcia ME, Sierra A, Garcia LF, Moreno AM,
Medina MC, Castan˜eda N, Silva-Diaz JF, Murcia M, Cardenas
SY, Dias da Silva WD, 1998. A randomized, blinded, compar-
ative trial of one pepsin-digested and two whole IgG anti-
venoms for Bothrops snake bites in Uraba, Colombia. Trop
Med Hyg 58: 183–189.
12. Otero-Patin˜o R, Segura A, Herrera M, Angulo Y, Leo´n G,
Gutie´rrez JM, Barona J, Estrada S, Perean˜ez A, Quintana
JC, Vargas LJ, Go´mez JP, Dı´az A, Sua´rez AM, Ferna´ndez J,
Ramı´rez P, Fabra P, Perea M, Ferna´ndez D, Arroyo Y,
Betancur D, Pupo L, Co´rdoba EA, Ramı´rez CE, Arrieta
AB, Rivero A, Mosquera DC, Conrado NL, Ortiz R, 2012.
Comparative study on the efficacy and safety of two poly-
valent, caprylic acid fractionated [IgG and F(ab’)2] antivenoms,
in Bothrops asper bites in Colombia. Toxicon 59: 344–355.
13. Otero R, Gutie´rrez JM, Rojas G, Nu´n˜ez V, Dı´az A, Miranda E,
Uribe AF, Silva JF, Ospina JG, Medina Y, Toro MF, Garcia
ME, Leo´n G, Garcia M, Lizano S, De La Torre J, Ma´rquez J,
Mena Y, Gonza´lez N, Arenas LC, Puzo´n A, Blanco N, Sierra
A, Espinal ME, Arboleda M, Jime´nez JC, Ramı´rez P, Dı´az M,
Guzma´n MC, Barros J, Henao S, Ramı´rez A, Macea U,
Lozano R, 1999. A randomized blinded clinical trial of two
antivenoms, prepared by caprylic acid or ammonium sulphate
fractionation of IgG, in Bothrops and Porthidium snake bites
in Colombia: correlation between safety and biochemical char-
acteristics of antivenoms. Toxicon 37: 895–908.
14. Herrera M, Leo´n G, Segura A, Meneses F, Lomonte B, Chippaux
JP, Gutie´rrez JM, 2005. Factors associated with adverse reac-
tions induced by caprylic acid-fractionated whole IgG prepara-
tions: comparison between horse, sheep and camel IgGs.
Toxicon 46: 775–781.
15. Theakston RDG,Warrell DA, Griffiths E, 2003. Report of aWHO
workshop on the standardization and control of antivenoms.
Toxicon 41: 541–557.
16. Mollnes TE, Hogasen K, De Carolis C, Vaquero E, Nielsen EW,
Fontana L, Perricone R, 1998. High-dose intravenous immuno-
globulin treatment activates complement in vivo. Scand J
Immunol 48: 312–317.
17. Garcı´a M, Monge M, Leo´n G, Lizano S, Segura E, Solano G,
Rojas G, Gutie´rrez JM, 2002. Effect of preservatives on IgG
aggregation, complement-activating effect and hypotensive
activity of horse polyvalent antivenom used in snakebite
envenomation. Biologicals 30: 143–151.
18. Sarma JV, Ward PA, 2011. The complement system. Cell
Tissue Res 343: 227–235.
19. dos Santos MC, D’Impe´rio Lima MR, Furtado GC, Colletto GM,
Kipnis TL, Dias da Silva W, 1989. Purification of F(ab’)2 anti-
snake venom by caprylic acid: a fast method for obtaining IgG
fragments with high neutralization activity, purity and yeld.
Toxicon 27: 297–303.
20. Rojas G, Jime´nez JM, Gutie´rrez JM, 1994. Caprylic acid fraction-
ation of hyperimmune horse plasma: description of a simple
procedure for antivenom production. Toxicon 32: 351–363.
21. Pidde-Queiroz G, Furtado MFD, Filgueiras CF, Pessoa LA,
Spadafora-Ferreira M, van den Berg CW, Tambourgi DV,
2010. Human complement activation and anaphylatoxins gen-
eration induced by snake venom toxins from Bothrops genus.
Mol Immunol 47: 2537–2544.
22. Laemmli UK, 1970. Cleavage of structural proteins during the
assembly of the head of bacteriophage T4.Nature 227: 680–685.
23. Morrissey JH, 1981. Silver stain for proteins in polyacrylamide
gels: a modified procedure with enhanced uniform sensitivity.
Anal Biochem 117: 307–310.
24. Towbin H, Staehelin T, Gordon J, 1979. Electrophoretic transfer
of proteins from acrylamide gels to nitrocellulose sheets: pro-
cedure and some applications. Proc Natl Acad Sci USA 76:
4350–4354.
25. Tanaka GD, Pidde-Queiroz G, Furtado MFD, van den Berg C,
Tambourgi DV, 2012. Micrurus snake venoms activate human
ANTICOMPLEMENTARY ACTIVITY OF ANTIVENOMS 583
complement system and generate anaphylatoxins.BMC Immunol
13: 4.
26. Solano S, Segura A, Leo´n G, Gutie´rrez JM, Burnouf T, 2012.
Low pH formulation of whole IgG antivenom: impact on
quality, safety, neutralizing potency and viral inactivation.
Biologicals 40: 129–133.
27. Dall’Acqua WF, Cook KE, Damschroder MM, Woods RM,
Wu H, 2006. Modulation of the effector functions of a human
IgG1 through engineering of its hinge region. J Immunol 177:
1129–1138.
28. Fumia S, Goede JS, Fischler M, Luginbu¨hl A, Frick S, Fodor P,
Lutz HU, 2008. Human F(ab’)2-containing immune complexes
together with anti-hinge natural antibodies stimulate com-
plement amplification in vitro and in vivo. Mol Immunol 45:
2951–2961.
29. Zhou W, 2012. The new face of anaphylatoxins in immune regu-
lation. Immunobiology 217: 225–234.
30. Otero R, Leo´n G, Gutie´rrez JM, Rojas G, Toro MF, Barona J,
Rodrı´guez V, Dı´az A, Nu´n˜ez V, Quintana JC, Ayala S,
Mosquera D, Conrado LL, Ferna´ndez D, Arroyo Y, Paniaqua
CA, Lo´pez M, Ospina CE, Alzate C, Ferna´ndez J, Meza JJ,
Silva JF, Ramı´rez P, Fabra PE, Ramı´rez E, Co´rdoba E, Arrieta
AB, Warrell DA, Theakston RD, 2006. Efficay and safety of
two whole IgG polyvalent antivenoms, refined by caprylic acid
fractionation with or without beta-propiolactone, in the treat-
ment of Bothrops asper bites in Colombia. Trans R Soc Trop
Med Hyg 100: 1173–1182.
31. Stone SF, Isbister GK, Shahmy S, Mohamed F, Abeysinghe C,
Karunathilake H, Ariaratnam A, Jacoby-Alner TE, Cotterell
CL, Brown SG, 2013. Immune response to snake envenoming
and treatment with antivenom; complement activation, cyto-
kine production and mast cell degranulation. PLoS Negl Trop
Dis 7: e2326.
32. Abubakar IS, Abubakar SB, Habib AG, Nasidi A, Durfa N,
Yusuf PO, Larnyang S, Garnvwa J, Sokomba E, Salako L,
Theakston RD, Juszczak E, Alder N, Warrell DA; Nigeria-
UK EchiTab Study Group, 2010. Randomised controlled
double-blind non-inferiority trial of two antivenoms for saw-
scaled or carpet viper (Echis ocellatus) envenoming in Nigeria.
PLoS Negl Trop Dis 4: e767.
33. Nezlin R, 2010. Interactions between immunoglobulin G mole-
cules. Immunol Lett 132: 1–5.
584 SQUAIELLA-BAPTISTA˜O AND OTHERS
